This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Antibodies as Drugs: Immunological Scaffolds as Therapeutics
joint with Tumor Immunology: Multidisciplinary Science Driving Combination Therapy
Organizer(s): Pablo Umaña, Mark X. Sliwkowski and Martin J. Glennie
Date: February 08 - 13, 2015
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by Genentech, Inc., ImmunoGen, Inc., Mersana Therapeutics, OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Shire Human Genetic Therapies
Summary of Meeting:
Monoclonal antibodies are now an established class of drugs in oncology and inflammation. In addition, exciting progress has been recently made on next-generation, engineered therapeutic antibodies and alternative immunological scaffolds, with the first examples from this class being recently approved by the FDA and EMA. This Keystone Symposia meeting will review progress in this area, including lessons learned in the clinic and how this can be applied to new targets and drug candidates. The meeting will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances in (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Tumor Immunology - Multidisciplinary Science Driving Combination Therapy,” which will be co-located with this meeting.
Scholarship Deadline: October 9 2014
Discounted Abstract Deadline: October 9 2014
Abstract Deadline: November 12 2014
Discounted Registration Deadline: December 9 2014
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Genentech, Inc.ImmunoGen, Inc.Mersana TherapeuticsOncoMed Pharmaceuticals, Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.Shire Human Genetic Therapies
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

AbbVie Inc.

Amgen Inc.

BioNTech RNA Pharmaceuticals GmbH

Celldex Therapeutics, Inc.

Genentech, Inc.

Heptares Therapeutics Ltd

Janssen R&D: Pharmaceutical Companies of Johnson & Johnson

MedImmune

Merrimack Pharmaceuticals

Molecular Partners AG

Regeneron Pharmaceuticals, Inc.

Roche Diagnostics GmbH
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI116024-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found